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The b2 adrenergic receptor (b2AR) undergoes desen-
sitization by a process involving its phosphorylation by
both protein kinase A (PKA) and G protein-coupled re-
ceptor kinases (GRKs). The protein kinase A-anchoring
protein AKAP79 influences b2AR phosphorylation by
complexing PKA with the receptor at the membrane.
Here we show that AKAP79 also regulates the ability of
GRK2 to phosphorylate agonist-occupied receptors. In
human embryonic kidney 293 cells, overexpression of
AKAP79 enhances agonist-induced phosphorylation of
both the b2AR and a mutant of the receptor that cannot
be phosphorylated by PKA (b2AR/PKA2). Mutants of
AKAP79 that do not bind PKA or target to the b2AR
markedly inhibit phosphorylation of b2AR/PKA2. We
show that PKA directly phosphorylates GRK2 on serine
685. This modification increases Gbg subunit binding to
GRK2 and thus enhances the ability of the kinase to
translocate to the membrane and phosphorylate the re-
ceptor. Abrogation of the phosphorylation of serine 685
on GRK2 by mutagenesis (S685A) or by expression of a
dominant negative AKAP79 mutant reduces GRK2-me-
diated translocation to b2AR and phosphorylation of
agonist-occupied b2AR, thus reducing subsequent re-
ceptor internalization. Agonist-stimulated PKA-medi-
ated phosphorylation of GRK2 may represent a mecha-
nism for enhancing receptor phosphorylation and
desensitization.
Hormonal signaling through G protein-coupled receptors
(GPCRs)1 is attenuated during prolonged exposure to agonist, a
process known as desensitization (1). One of the initial events
in this multistep process is the phosphorylation of agonist-
occupied receptor molecules. Two families of kinases are re-
sponsible for the phosphorylation of GPCRs, the second mes-
senger-activated kinases (PKA and PKC) and the GPCR
kinases (GRKs 1–7) (2–8). Although the second messenger-
activated kinases are capable of phosphorylating receptors in
the absence or presence of agonist, the GRKs specifically phos-
phorylate only agonist-occupied receptors (5, 9). Moreover,
phosphorylation by GRKs leads to the recruitment of the ar-
restin proteins to the phosphorylated receptors, preventing
further coupling to G proteins (1). In the case of the prototypic
b2 adrenergic receptor (b2AR), agonist stimulation leads to the
recruitment of cytosolic GRK2 to the plasma membrane where
it binds to and phosphorylates the receptor. The mechanisms
by which different GRKs are recruited to the receptor varies,
but for both GRK2 and GRK3, recruitment is achieved through
the binding of phospholipids and Gbg subunits to the COOH-
terminal pleckstrin homology domain of the kinase (10–16). As
the recruitment requires the presence of free Gbg subunits, the
binding of the kinase to the receptor only occurs at times when
the receptor is signaling through coupling to G proteins. In this
manner, the kinase is only delivered at times when there are
agonist-occupied receptor substrates for it to phosphorylate.
The second messenger-activated kinases are constitutively
localized to subcellular structures via their interactions with
anchoring proteins (17). In the case of PKA, its localization is
achieved through a family of A kinase-anchoring proteins
(AKAPs) that were originally identified by their ability to in-
teract with PKA regulatory subunits II (18). The AKAPs are
responsible for the localization of PKA to particular subcellular
compartments, including the plasma membrane, mitochondria,
post-synaptic densities, and centrosomes (19–27). Some of the
AKAPs have been shown to exist in complexes containing a
number of other signaling molecules, including the N-methyl-
D-aspartate receptor, ion channels, GPCRs, and protein phos-
phatases (27–33). These discoveries have led to the hypothesis
that AKAPs may act as nodes at which cross-talk between
different signaling events may be coordinated (34). One family
member, AKAP79 (human AKAP79, rodent AKAP150, and bo-
vine AKAP75), binds not only to PKA but also to PKC and the
protein phosphatase 2B (20, 34–37). AKAP79 has also been
shown to be responsible for the association of PKA with the
plasma membrane and with integral membrane proteins in-
cluding the b2AR (27). It has been demonstrated that the
overexpression of AKAP79 with the b2AR enhances receptor
phosphorylation and, furthermore, that mutants of AKAP79,
which fail to bind to the b2AR or to PKA, are effective at
* This work was supported in part by National Institutes of Health
Grants HL16037 (to R. J. L) and GM48231 (to J. D. S). The costs of
publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement”
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Present address: Division of Biology, California Inst. of Technology,
12000 E. California Blvd., Pasadena, CA 91125.
¶ Present address: Medical Research Council Laboratory of Molecu-
lar Cell Biology, University College London, Gower St., London WC1E
6BT, United Kingdom.
iInvestigators of the Howard Hughes Medical Institute
** To whom correspondence should be addressed: Howard Hughes
Medical Inst., Box 3821, Duke University Medical Center, Durham, NC
27710. Tel.: 919-684-2974; Fax: 919-684-8875; E-mail: lefko001@
receptor-biol.duke.edu.
1 The abbreviations used are: GPCR, G protein-coupled receptor;
AKAP, A kinase-anchoring protein; PKA, protein kinase A; PKC, pro-
tein kinase C; b2AR, b2 adrenergic receptor; HEK, human embryonic
kidney; GRK, G protein-coupled receptor kinase; GST, glutathione S-
transferase; PAGE, polyacrylamide gel electrophoresis; Erk1/Erk2, ex-
tracellular signal-regulated kinase 1 and/or 2.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 276, No. 18, Issue of May 4, pp. 15192–15199, 2001
© 2001 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org15192
reducing phosphorylation. In this manner, AKAP79 may be
acting as a scaffold which coordinates the events involved in
receptor desensitization. To investigate this novel function of
AKAP79 further, we set out to test whether another event
involved in b2AR desensitization, i.e. receptor phosphorylation
by GRK2, is modulated by PKA scaffolding.
EXPERIMENTAL PROCEDURES
Materials
GRK2 was purified from baculovirus-infected Sf9 cells as described
previously (38). Bovine GRK2ct (residues 467–689) was expressed as a
glutathione S-transferase (GST) fusion protein in bacteria and purified
as described previously (13). Purification of rod outer segment mem-
branes (39), Gbg subunits, (40) and tubulin (41) was described previ-
ously. AKAP79, AKAP79pro, and AKAP79108–427 mammalian expres-
sion constructs were described previously (27, 37). Mammalian
expression constructs of FLAG epitope-tagged b2 adrenergic receptor
(b2AR) and b2AR/PKA2 mutant receptor (PKA phosphorylation sites
serines 261, 262, 345, and 346 all mutated to alanines) were described
previously (42). The PKA catalytic subunit was purchased from Pro-
mega, and the anti-Gb antibody was from Perkin Elmer Life Sciences.
The anti-GRK2 monoclonal and AKAP79 polyclonal antibodies were
described previously (20, 42). M2 anti-FLAG antibody conjugated to
Sepharose beads and M2 antibody were from Sigma. Unless otherwise
stated, the chemicals were from Sigma.
Plasmid Constructs
Construction of the pcDNA3-Bovine GRK2 Mutant S685A—
pcDNA1-bovine GRK2 (43) was restriction digested with HindIII and
XbaI, and the insert was ligated into the pcDNA3 vector (Invitrogen). A
single point mutation changing serine 685 to alanine was introduced by
the polymerase chain reaction using the primers 59-TCCCCAACCGC-
CTCGAGTGGC-39 and 59-CTAGTCTAGATCAGAGGCCGTTGGCG-
GCGCCGCGC-39. The polymerase chain reaction product was restric-
tion digested with XhoI and XbaI and used to replace the equivalent
fragment in the pcDNA3 construct. The sequence and orientation of the
clone were confirmed by automated DNA sequence analysis.
Construction of a COOH-terminal Truncated GRK2D19 Baculovirus
Plasmid—The RsrII/BamHI restriction fragment from a GRK2D19 con-
struct (construct 2 in Ref. 13 encoding full-length GRK2 with a stop
codon inserted at codon 671) was used to replace the equivalent frag-
ment in pVL1392-GRK2(S670A) (44). The orientation and sequence of
the clone were confirmed by automated DNA sequence analysis. Puri-
fication of the expressed protein from Sf9 cells was identical as that
described for full-length GRK2 (38).
Methods
Cell culture, Immunoprecipitations, and Immunoblotting—HEK293
cells were grown at 37 °C in minimal essential medium containing 10%
fetal bovine serum and 13 penicillin/streptomycin (Life Technologies,
Inc.) under 5% CO2. Cells at 60% confluence were transfected with up
to 5 mg of plasmid DNA and 15 ml of Fugene 6 (Roche Molecular
Biochemicals). Two days after transfection, cells were lysed in radioim-
mune precipitation buffer (150 mM NaCl, 50 mM Tris, pH 8.0, 5 mM
EDTA, 1% v/v Nonidet P-40, 0.5% w/v sodium deoxycholate, 10 mM
NaF, 10 mM Na2-pyrophosphate, 0.1% w/v SDS, 5 mg/ml aprotinin, 150
mg/ml benzamidine, 5 mg/ml leupeptin, 4 mg/ml pepstatin, and 20 mg/ml
phenylmethylsulfonyl fluoride). If cross-linking of proteins was neces-
sary before immunoprecipitation, cells were incubated at room temper-
ature for 20 min in phosphate-buffered saline containing 10 mM
HEPES, pH 7.4, and 1 mg/ml dithiobis(succinimidyl propionate) before
lysis in radioimmune precipitation buffer (45). After removal of insolu-
ble cell debris by centrifugation, protein concentrations were equalized
FIG. 1. Effects of PKA anchoring on
b2AR and b2AR/PKA2 phosphoryla-
tion. A, agonist-stimulated b2AR phospho-
rylation is regulated by AKAP79. HEK293
cells overexpressing FLAG-b2AR were tran-
siently transfected with AKAP79 or the mu-
tant AKAP79108 – 427 and incubated in
[32P]orthophosphate. Cells were stimulated
with 10 mM isoproterenol (iso) for 5 min, and
FLAG-b2AR was immunoprecipitated and
resolved by SDS-PAGE. Upper panel shows
a representative autoradiogram (n 5 4) with
basal (2) and isoproterenol-stimulated (1)
b2AR phosphorylation in transfected cells as
indicated. AKAP79 and AKAP79108–427 ex-
pression was detected in cell lysates by im-
munoblotting (IB, lower panel). B, agonist-
stimulated b2AR/PKA2 phosphorylation is
regulated by AKAP79. HEK293 cells ex-
pressing FLAG-b2AR/PKA2 were tran-
siently transfected with AKAP79,
AKAP79pro, or AKAP79108–427, and isopro-
terenol-stimulated phosphorylation of
b2AR/PKA2 was measured as described
earlier. The graph shows the mean levels of
phosphorylation of b2AR/PKA2 relative to
control transfected cells. AKAP79,
AKAP79pro, and AKAP79108–427 expression
were detected in cell lysates by immunoblot-
ting (lower panel). C, AKAP79 regulates
b2AR/PKA2 phosphorylation by GRK2.
HEK293 cells expressing b2AR/PKA2 were
transiently transfected with GRK2,
AKAP79, AKAP79pro, and AKAP79108–427
as indicated. Isoproterenol-stimulated phos-
phorylation of b2AR/PKA2 was measured
as described earlier. Expression of AKAP79,
its mutants, and GRK2 was confirmed by
immunoblotting (lower panels). D, b2AR/
PKA2 cannot be phosphorylated by PKA.
FLAG-b2AR or FLAG-b2AR/PKA2 was
transfected into HEK293 cells. Cells were
subsequently stimulated with 10 mM isopro-
terenol or 10 mM vasoactive intestinal pep-
tide (VIP) for 5 min, and 32P incorporation
was measured. The graphs show the
mean 6 S.E. of three experiments.
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in all samples, and FLAG epitope-tagged proteins were immunoprecipi-
tated for 15 h with 40 ml of a 1:1 slurry of M2 anti-FLAG antibody
covalently coupled to Sepharose beads. The beads were washed four
times with radioimmune precipitation buffer, and bound proteins were
eluted in 50 ml of 23 SDS-PAGE sample buffer (100 mM Tris, pH 7.2, 4%
w/v SDS, 200 mM dithiothreitol, 20% v/v glycerol, 20 mg/ml bromphenol
blue with 5% v/v b-mercaptoethanol for cross-linked samples) for 10
min at 95 °C. Samples were resolved on 10% or 4–20% polyacrylamide
gels (Novex) and transferred to nitrocellulose filters for immunoblot-
ting. Filters were blocked with 5% w/v fat-free milk powder in Tris-
buffered saline with Tween 20 (20 mM Tris, pH 7.4, 500 mM NaCl, 0.1%
v/v Tween 20) and incubated overnight at 4 °C with appropriate pri-
mary antiserum. After thorough washing in Tris-buffered saline with
Tween 20, filters were incubated for 1 h with horseradish peroxidase-
conjugated anti-rabbit or mouse secondary antibody (Amersham Phar-
macia Biotech), washed again with Tris-buffered saline with Tween 20,
immersed in ECL reagent (Amersham Pharmacia Biotech), and ex-
posed to x-ray film.
Receptor Sequestration Assay—COS7 cells expressing FLAG-b2AR/
PKA2 alone or coexpressing AKAP79 with GRK2 or GRK2S685A were
stimulated with 10 mM isoproterenol for 30 min. Agonist-induced recep-
tor internalization was measured as the loss of cell surface FLAG
epitopes available for M2 antibody binding by detection of a fluores-
cently labeled secondary antibody as described previously (46).
Receptor Phosphorylation Assay—Receptor phosphorylation was as-
sessed after the labeling of the intracellular ATP pool of HEK293 cells
stably transfected with FLAG-b2AR or FLAG-b2AR/PKA2 with
[32P]orthophosphate (PerkinElmer Life Sciences) as described previ-
ously (43). Cells were labeled for 1 h at 37 °C in phosphate-free Dul-
becco’s modified Eagle’s medium containing 10 mM HEPES, pH 7.4, 100
mCi/ml [32P]orthophosphate, and 1 mg/ml microcystin L-R (Calbiochem).
Cells were stimulated with 10 mM isoproterenol for 5 min, washed twice
with ice-cold phosphate-buffered saline buffer, solubilized in 750 ml of
radioimmune precipitation buffer, and equivalent protein amounts
were subjected to immunoprecipitation. Samples were resolved on 10%
polyacrylamide gels and dried under vacuum. Radioactive bands were
visualized and quantified using a PhosphorImager (Molecular Dynam-
ics) and by exposure to x-ray film. The levels of receptor expression were
measured by flow cytometry by detecting cell surface-bound anti-
epitope tag M2 antibodies and fluorescein-conjugated secondary anti-
bodies (46). All phosphorylation levels were normalized to receptor
expression and are shown as stimulated-basal values.
In Vitro PKA-mediated Phosphorylation of Full-length and Frag-
ments of GRK2—One microgram of GRK2 or GRK2D19 purified from
baculovirus-infected Sf9 cells or GRK2ct purified by cleavage with
thrombin from bacterially expressed GST fusion protein (13) was incu-
bated with 1 unit of PKA catalytic subunit (Promega) in phosphoryla-
tion reaction buffer containing 20 mM Tris, pH 7.5, 10 mM MgCl2, 2 mM
EDTA, 1 mM dithiothreitol, 60 mM [g32P]ATP (;1000 cpm/pmol), 1
mg/ml phospholipids (crude preparation containing 20% w/v L-a-phos-
phatidylcholine, Sigma), and 0.8 mM Gbg subunits. After 30 min of
incubation at 30 °C, reactions were stopped by the addition of an equal
volume of 23 SDS-PAGE sample buffer. Samples were boiled for 10 min
and resolved on 4–20% gradient polyacrylamide gels. Radioactive
bands in dried gels were visualized and quantified using a Phospho-
rImager and by exposure to x-ray film.
GRK2-mediated Phosphorylation of Protein Substrates—In vitro
phosphorylation of rhodopsin, tubulin, and the peptide substrate
RRRREEEEESAAA by GRK2 was performed as described previously
(47). The reactions used 25 ng of GRK2 to phosphorylate 2 mg of
rhodopsin or 100 ng of GRK2 to phosphorylate either 0.2 mg of tubulin
or 1 mM peptide substrate.
In Vitro Binding of Gbg to GST-GRK2ct—One microgram of GST-
GRK2ct (residues 467–689 of bovine GRK2) bound to glutathione-
conjugated Sepharose 4B beads (Calbiochem) was incubated with or
without PKA as described above. After 30 min of incubation at 30 °C,
beads were washed extensively with phosphate-buffered saline contain-
ing 0.01% v/v lubrol to remove all the PKA and ATP. Four micrograms
of Gbg from bovine brain was then added and incubated at 4 °C for 2 h.
After extensive washes with phosphate-buffered saline containing
0.01% lubrol, 23 sample buffer was added, and proteins were eluted by
boiling for 10 min. Samples were resolved on 4–20% polyacrylamide
gels, transferred to nitrocellulose filters, and immunoblotted with an
antibody recognizing Gb subunits.
RESULTS
It has been shown previously that the protein kinase A-an-
choring protein AKAP79 can directly interact with and regu-
late the phosphorylation of the b2AR (27). In HEK293 cells
overexpressing FLAG epitope-tagged b2AR, the coexpression of
AKAP79 increases b2AR phosphorylation by 40%, whereas the
coexpression of the AKAP79 mutant AKAP79108–427, which
does not bind to the receptor or localize PKA to the membrane,
impairs receptor phosphorylation by 50% (Fig. 1A). To deter-
mine whether this enhancement of b2AR phosphorylation is a
result of AKAP79 directly facilitating phosphorylation of the
receptor by PKA, agonist-induced phosphorylation of a FLAG
epitope-tagged b2AR mutant lacking all PKA phosphorylation
sites (b2AR/PKA2) was measured. Surprisingly, the coexpres-
sion of wild type AKAP79 enhances agonist-induced phospho-
rylation of b2AR/PKA2 by 40% (Fig. 1B). In contrast, cells
transfected with either of two AKAP79 mutants that are un-
able to target PKA to the plasma membrane, AKAPpro and
AKAP108–427, exhibit a 55–70% decrease in b2AR/PKA2 phos-
phorylation. AKAP79pro is targeted to the plasma membrane
and can bind to b2AR but is unable to bind to the PKA regu-
latory subunit, whereas AKAP79108–427 binds to PKA but lacks
the receptor and membrane-targeting domain (27, 37). Al-
though GRK2 and AKAP79 do not interact directly (data not
shown), when GRK2 and AKAP79 are overexpressed together a
2.3-fold increase in b2AR/PKA2 phosphorylation is observed
compared with a 1.4-fold increase by overexpression of GRK2
alone (Fig. 1C). Overexpression of either of the two AKAP79
mutants with GRK2 inhibits receptor phosphorylation by 40–
60% compared with control cells expressing only endogenous
levels of GRK2 (Fig. 1C).
These results suggest that AKAP79 does not affect b2AR
phosphorylation by simply enhancing direct receptor phospho-
rylation by PKA. Rather, they suggest that AKAP79 enhances
GRK2-mediated phosphorylation of the b2AR. To ensure that
PKA is not capable of phosphorylating the b2AR/PKA2 mu-
tant, the phosphorylation of the wild type receptor and b2AR/
FIG. 2. Effect of PKA-mediated
phosphorylation of GRK2 on rhodop-
sin phosphorylation. Twenty-five
nanograms of GRK2 phosphorylated by
PKA (closed symbols) or not (open sym-
bols) was used to phosphorylate 2 mg of
rhodopsin in the presence of 0, 100, or 167
nM Gbg. Phosphorylation reactions were
performed at 30 °C for the indicated
times. Reactions were stopped by the ad-
dition of an equal volume of 23 SDS-
PAGE sample buffer, resolved by SDS-
PAGE, and radioactive bands were
quantified using a PhosphoImager. The
results shown are representative of three
experiments.
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PKA2 was compared following activation of PKA by stimula-
tion of a coexpressed Gs-coupled receptor (Fig. 1D). In the
absence of its ligand, the b2AR can be phosphorylated by PKA
but not by the GRKs as they specifically phosphorylate only
agonist-occupied receptors. Stimulation of endogenous vasoac-
tive intestinal peptide receptors leads to the phosphorylation of
wild type b2AR to 20% of the level observed with isoproterenol
stimulation (Fig. 1D). This level is consistent with previous
reports for PKA phosphorylation of the b2AR in HEK293 cells
(48). The b2AR/PKA2 mutant, however, shows no vasoactive
intestinal peptide-induced phosphorylation (Fig. 1D), confirm-
ing that the removal of the PKA phosphorylation sites renders
the receptor incapable of being further phosphorylated by PKA.
Taken together, the regulation of b2AR/PKA2 phosphorylation
by wild type and mutants of AKAP79 indicates that AKAP79
may indirectly regulate GRK2 activity by a mechanism requir-
ing the anchoring of PKA to the plasma membrane.
To further test the ability of PKA to affect GRK2 activity
against receptor substrates, we measured the effect of PKA on
GRK2-mediated phosphorylation of rhodopsin in vitro. Incuba-
tion with PKA and 167 nM Gbg subunits or with GRK2 alone
results in little or no phosphorylation of rhodopsin (Fig. 2).
However, with the addition of increasing concentrations of Gbg
subunits, GRK2 phosphorylation of rhodopsin is greatly in-
creased and is further enhanced with the addition of PKA. As
PKA does not significantly phosphorylate rhodopsin nor is its
activity regulated by Gbg subunits, the observed increase in
phosphorylation is attributed to enhanced GRK2 activity to-
ward rhodopsin.
It has been reported that PKC can directly phosphorylate
GRK2 at a site within the carboxyl terminus and that this
facilitates GRK2 translocation to the plasma membrane (49,
50). To investigate whether a similar mechanism exists for the
phosphorylation of GRK2 by PKA, we tested the ability of PKA
to phosphorylate purified full-length GRK2 and fragments of
GRK2 (Fig. 3A). In the presence of phospholipids that activate
GRK2, bovine GRK2 purified from Sf9 cells shows weak auto-
phosphorylation (a stoichiometry of 0.03 mol of phosphate/mol
of protein, Fig. 3B). Incubation of GRK2 with PKA leads to a
significant increase in phosphorylation (0.25 mol of phosphate/
mol of protein), which is further enhanced by the addition of 0.8
mM Gbg subunits to 0.7 mol of phosphate/mol of protein. A
fragment of the carboxyl terminus of GRK2 (residues 467–689,
GRK2ct), which encompasses the pleckstrin homology domain
and Gbg binding domain, also acts as a good PKA substrate
(0.4 mol of phosphate/mol of protein), and this phosphorylation
is markedly enhanced by the addition of Gbg subunits (0.7 mol
of phosphate/mol of protein, Fig. 3B). Furthermore, a GRK2
mutant that lacks 19 residues at the carboxyl terminus is
unable to be phosphorylated by PKA (Fig. 3B).
Examination of the extreme COOH-terminal sequence of
GRK2 reveals three potential sites of PKA phosphorylation,
serines 670, 676, and 685. Although the phosphorylation of
serine 670 by Erk1/Erk2 was reported previously to inactivate
GRK2 (44), no studies have investigated whether phosphoryl-
ation of serines 676 and 685 can affect GRK2 activity. The site
of PKA phosphorylation on GRK2 was mapped by incubating
the GRK2 carboxyl terminus fragment with PKA and
[g-32P]ATP followed by tryptic digestion and subsequent high
pressure liquid chromatography fractionation and sequencing
FIG. 3. Identification of GRK2 as a
PKA substrate. A, schematic represen-
tation of GRK2 fragments used as sub-
strates in PKA phosphorylation assays.
Full-length GRK2 (residues 1–689) con-
tains a central catalytic domain (residues
188–467) and a COOH-terminal pleck-
strin homology domain (PH domain, res-
idues 533–651) . The GRK2ct fragment
(residues 467–689) contains only the
pleckstrin homology domain, and
GRK2D19 is identical to full-length GRK2
but with the last 19 residues deleted. B,
purified wild type and fragments of GRK2
were phosphorylated by PKA for 30 min
at 30 °C in the presence of [g232P]ATP,
phospholipids, and with or without Gbg
subunits added. Samples were resolved
by SDS-PAGE. Shown are representative
autoradiograms from three experiments.
C, sequence of the last 49 amino acids of
GRK2 with potential serine phosphoryla-
tion sites shown in bold and the PKA
phosphorylation site, serine 685, marked
with an asterisk.
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of radiolabeled peptides. This yields one major phosphopeptide
corresponding to residues 678–689 of GRK2 containing a sin-
gle site of phosphorylation at serine 685. Taken together, these
data show that PKA is capable of phosphorylating GRK2 at a
specific site within the carboxyl terminus and that this phos-
phorylation is markedly enhanced by the presence of Gbg.
PKA phosphorylation of GRK2 could lead to enhanced phos-
phorylation of receptors by two mechanisms; either the cata-
lytic activity of GRK2 is enhanced by its phosphorylation or
GRK2 targeting to the plasma membrane is increased, possibly
in a Gbg subunit-dependent manner. To test whether PKA
phosphorylation of GRK2 leads to a direct enhancement of
GRK2 catalytic activity, the ability of GRK2 to phosphorylate
nonreceptor substrates (a peptide substrate and tubulin) was
compared with and without phosphorylation of GRK2 by PKA
(Fig. 4). Incubation with PKA alone weakly phosphorylates
tubulin and fails to phosphorylate the peptide substrate (data
not shown), whereas incubation with GRK2 leads to significant
phosphorylation of both substrates (0.25 mol of phosphate/mol
of protein for the peptide substrate (Fig. 4A) and 0.3 mol of
phosphate/mol of protein for tubulin (Fig. 4B)). Incubation of
the substrates with both PKA and GRK2 under conditions that
permit GRK2 phosphorylation by PKA shows no increase in the
level of substrate phosphorylation, indicating that PKA phos-
phorylation of GRK2 does not directly affect its catalytic
activity.
To test whether PKA phosphorylation of GRK2 enhances the
interaction between GRK2 and Gbg subunits, a GST fusion of
the carboxyl terminus of GRK2 immobilized on glutathione-
Sepharose beads was phosphorylated by PKA and then incu-
bated with purified Gbg subunits. After washing, the amount
of Gbg bound to the fusion protein was monitored by Western
blotting for Gb subunits (Fig. 5). Before phosphorylation by
PKA, the GST-GRK2ct is capable of binding Gbg subunits.
After phosphorylation, the binding of Gbg is increased by 64 6
25%, whereas GST alone binds Gbg very poorly. This finding
shows that phosphorylation by PKA indeed enhances the abil-
ity of GRK2 to bind Gbg subunits, and this could represent the
mechanism by which GRK2 phosphorylation of receptors is
regulated by factors affecting PKA activity in cells.
Upon agonist stimulation, GRK2 translocates to the plasma
membrane by virtue of its interaction with Gbg subunits (13–
16, 51, 52). If the stability of this interaction is partly depend-
ent on PKA-mediated phosphorylation of GRK2, the removal of
PKA from the membrane should also inhibit GRK2 transloca-
tion. To test this theory, the ability of GRK2 to interact with
the b2AR in cells coexpressing AKAP79 was examined (Fig. 6).
Cells coexpressing the FLAG epitope-tagged b2AR, GRK2, and
either AKAP79 or AKAP79108–427 were stimulated for 5 min
with 10 mM isoproterenol. Cells were then treated with a cell
permeant cross-linker, and the b2AR was immunoprecipitated
from the cell lysates. The amount of GRK2 present in the
immune complex was detected by Western blotting. Overex-
pression of AKAP79108–427 impairs GRK2 translocation to
b2AR by 40 6 15% (Fig. 6A), demonstrating that a mutant
AKAP79 that reduces PKA association with the plasma mem-
brane does indeed decrease GRK2 association with the b2AR.
The role that PKA phosphorylation of GRK2 plays in the
colocalization of GRK2 with the b2AR was further demon-
strated by mutating serine 685 in GRK2 to alanine
(GRK2S685A) and comparing it to the wild type kinase in its
ability to associate with the receptor. The GRK2S685A mutant
lacking the PKA phosphorylation site of the native GRK2
should not show PKA-mediated enhancement of translocation.
FIG. 4. Effect of PKA on GRK2-mediated phosphorylation of
peptide and tubulin. GRK2 was incubated with [g32P]ATP and 1 mM
peptide RRRREEEEESAAA (A) or 0.2 mg of tubulin (B) in the presence
(M) or absence (f) of PKA. Phosphorylation reactions were performed at
30 °C for the indicated times. Incorporation of 32P was measured as
described under “Experimental Procedures.” Basal PKA-mediated
phosphorylation of tubulin has been subtracted in lower panel. The
results are representative of three experiments.
FIG. 5. Measurement of the effect of phosphorylation of
GRK2ct by PKA on Gbg subunit binding. The GST fusion protein of
GRK2ct immobilized on glutathione-Sepharose beads was incubated
with 4 mg of purified Gbg subunits before and after phosphorylation of
the fusion protein with PKA. After washing, samples were resolved by
SDS-PAGE and transferred to nitrocellulose filters. The amount of Gbg
bound to the fusion protein or control GST was detected by immuno-
blotting with an anti-Gb subunit antibody (upper panel). Relative
amounts of Gbg bound by the fusion protein with (1PKA) and without
(control) phosphorylation by PKA were quantified from three experi-
ments (lower panel).
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Indeed, a 40% impairment in the agonist-stimulated associa-
tion of GRK2S685A with b2AR compared with wild type GRK2
is observed (Fig. 6B).
We also predicted that coexpression AKAP79 with
GRK2S685A, unlike with wild type GRK2, should not enhance
b2AR/PKA2 phosphorylation. When tested in vitro against
nonreceptor substrates, the mutant and wild type GRK2
showed no detectable differences in their catalytic activities
(data not shown). Coexpression of wild type GRK2 with
AKAP79 enhances receptor phosphorylation and subsequently
leads to enhanced levels of receptor internalization when com-
pared with control transfected cells (Fig. 7A). Coexpression of
GRK2S685A with AKAP79, however, fails to significantly en-
hance b2AR/PKA2 phosphorylation, confirming that preven-
tion of PKA-mediated phosphorylation of GRK2 at serine 685
impairs the ability of the kinase to both associate with and
phosphorylate the b2AR in response to agonist. As a conse-
quence of enhancing agonist-induced b2AR/PKA2 phosphoryl-
ation by the coexpression of GRK2 and AKAP79, receptor in-
ternalization is increased (Fig. 7B). Coexpression of
GRK2S685A and AKAP79, however, does not increase receptor
internalization, mirroring the failure of the mutant kinase to
enhance receptor phosphorylation.
DISCUSSION
The b2AR exists in a complex with AKAP79/AKAP150 and
associated signaling proteins including PKA in rat brain tissue
(27). Enhancement or perturbation of the complex in HEK293
cells leads to alterations in phosphorylation of the b2AR. This
originally was assumed to occur primarily through the effects
of PKA on the receptor. However, we now show that receptor
phosphorylation by GRK2 is also affected by AKAP79. In
HEK293 cells, the relative contributions of PKA and GRK2 to
agonist-induced b2AR phosphorylation are ;20 and 80%, re-
spectively (48). When AKAP79 is overexpressed in cells, a 40%
enhancement in the level of receptor phosphorylation is ob-
served, whereas the disruption of this complex with a mutant of
AKAP79 reduces receptor phosphorylation by 50% (Fig. 1A). If
the ability of AKAP79 to affect b2AR phosphorylation relates
entirely to the phosphorylation of the receptor by PKA, then at
most a 20% reduction in phosphorylation would be expected.
This disparate finding led us to explore the possibility that
AKAP79 somehow regulates the ability of GRKs to phospho-
rylate their receptor substrates. We confirmed this observation
by demonstrating that phosphorylation of a mutant b2AR that
is not a PKA substrate is also regulated by AKAP79 (Fig. 1,
B–D). Furthermore, in vitro phosphorylation of rhodopsin by
FIG. 6. The effects of overexpression of AKAP79 and
GRK2S685A on GRK2 recruitment to the stimulated b2AR. A,
HEK293 cells were transfected with GRK2 alone or with GRK2, the
FLAG epitope-tagged b2AR, and either the wild type AKAP79 or the
AKAP79108–427 mutant. After stimulation with 10 mM isoproterenol
(iso), the cells were treated with a cell permeant cross-linker, lysates
were prepared, and the b2AR was immunoprecipitated with M2 anti-
body (IP: FLAG-b2AR). The amount of GRK2 present in the immune
complex was detected by immunoblotting (IB: GRK2) with an anti-
GRK2 monoclonal antibody (upper panel arrow). Expression in lysates
of GRK2 (middle panel arrow), AKAP79 (lower panel arrow), and
AKAP79108–427 (lower panel arrowhead) were confirmed by immuno-
blotting. B, HEK293 cells were transfected with GRK2 or the
GRK2S685A mutant with or without the FLAG epitope-tagged b2AR.
After stimulation with 10 mM isoproterenol and cross-linking, the b2AR
was immunoprecipitated (IP: FLAG-b2AR) with M2 antibody. The
amount of GRK2 or GRK2S685A present in the immune complex (upper
panel arrow) and in the lysate (lower panel arrow) was detected by
immunoblotting (IB: GRK2). Gels are representative of three
experiments.
FIG. 7. Mutation of serine 685 to alanine on GRK2 impairs
GRK2-mediated b2AR/PKA2 phosphorylation and internaliza-
tion. A, HEK293 cells expressing FLAG-b2AR/PKA2 were transiently
transfected with wild type GRK2 or the mutant GRK2S685A and with
AKAP79. Cells were labeled with [32P]orthophosphate, stimulated with
10 mM isoproterenol for 5 min, and the b2AR/PKA2 was immunopre-
cipitated. The graph shows the mean of agonist-stimulated phosphoryl-
ation of b2AR/PKA2 relative to nontransfected cells. The values are
normalized to receptor expression levels as described under “Experi-
mental Procedures.” B, COS7 cells transiently transfected with FLAG-
b2AR/PKA2 alone or with AKAP79 and GRK2 or GRK2S685A were
treated with 10 mM isoproterenol for 30 min, and the amount of recep-
tors internalized was measured. The graph shows the mean 6 S.E. from
four experiments. *, p , 0.05 when compared with mock transfected
cells.
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GRK2 is enhanced in the presence of PKA and Gbg subunits,
even though rhodopsin itself is not a PKA substrate (Fig. 2).
The mechanism underlying these findings appears to be the
ability of PKA to phosphorylate GRK2 at a specific residue,
serine 685 (Fig. 3). Phosphorylation at this site does not alter
the kinase activity of GRK2 per se (Fig. 4). Rather, it leads to
the enhanced binding of GRK2 to Gbg subunits, which should
increase the association of the kinase with receptor substrates
(Fig. 5). We also demonstrate that the ability of PKA to phos-
phorylate GRK2 in vitro is enhanced in the presence of Gbg
subunits, suggesting that in cells PKA may preferentially phos-
phorylate those GRK2 molecules already complexed with Gbg
subunits at the membrane. Therefore, phosphorylation by PKA
may be involved both in promoting translocation of GRK2 to
the membrane and in maintaining GRK2 in a Gbg-bound form
once there.
We confirmed the role of PKA phosphorylation in GRK2
membrane translocation by showing that the mutation of the
PKA phosphorylation site in GRK2 (serine 685 to alanine)
diminishes the ability of GRK2 to be recruited to b2AR and
phosphorylate the b2AR (Figs. 6 and 7). The phosphorylation of
GRK2 by PKA was also shown to have a functional conse-
quence as overexpression of GRK2, but not GRK2S685A, leads
to enhanced receptor internalization in response to agonist
(Fig. 7B). Tethering of PKA to the b2AR via AKAP79, there-
fore, may represent a regulatory loop whereby agonist-stimu-
lated coupling of the b2AR to Gs, resulting in the production of
cAMP, is attenuated by the cAMP-activated kinase PKA phos-
phorylating both the receptor and the major desensitizing ki-
nase, GRK2. This process leads to increased translocation of
GRK2 to the receptor by enhanced binding to Gbg subunits,
resulting in further receptor phosphorylation, desensitization,
and internalization (Fig. 8).
A similar mechanism may also exist for the recruitment of
GRK2 to the receptor following phosphorylation of GRK2 by
PKC. Earlier studies have shown that activation of the cellular
pool of PKC with phorbol 12-myristate 13-acetate leads to the
translocation of cytosolic GRK2 to the plasma membrane (49,
50). A site of robust PKC phosphorylation on GRK2 has been
mapped partially to within the COOH-terminal domain, and it
has been demonstrated that such phosphorylation leads to
enhanced Gbg-dependent GRK2 activity toward a purified re-
ceptor substrate.
AKAP79 acts as a scaffolding protein for both PKA and PKC,
associating both kinases with the plasma membrane and the
b2AR. Therefore, it is feasible that AKAP79 also modulates the
ability of PKC to affect membrane recruitment of GRK2. If this
is the case, AKAP79 might represent a general scaffold for
regulating membrane recruitment of GRK2 by second messen-
ger-activated kinase phosphorylation. It will be interesting to
determine whether the site of PKC phosphorylation on GRK2 is
the same as or different from that of PKA and whether such
phosphorylation also enhances Gbg binding. It is also worthy to
note that GRK5 can be phosphorylated by PKC at sites near
the carboxyl terminus, but unlike GRK2, this phosphorylation
inhibits GRK5 activity (53). Similarly, phosphorylation of
GRK2 by Erk1 or Erk2 on serine 670 leads to an almost com-
plete inhibition of the kinase (44). This may represent a mech-
anism by which GRK2 is returned to an inactive state after it
has phosphorylated agonist-occupied receptors. PKC phospho-
rylation of GRK5, therefore, seems more analogous to the Erk1/
Erk2 phosphorylation of GRK2 rather than to GRK2 phospho-
rylation by either PKA or PKC. These marked differences in
regulatory phosphorylation imply that the roles of these two
GRKs in GPCR regulation are very different.
It has been reported recently that gravin (AKAP250) can also
FIG. 8. Schematic representation of the role of AKAP79 in reg-
ulating receptor phosphorylation by GRK2. The receptor (black) in
the absence of the bound hormone (H) is associated with PKA via its
interaction with the PKA regulatory subunits II through AKAP79. On
agonist binding (Stimulation), the receptor couples to the heterotrim-
eric Gs protein, leading to the dissociation of the a-subunits and bg-
subunits. Gas activates the adenylate cyclase enzyme (AC) in the mem-
brane, which converts ATP to cyclic AMP (cAMP). The binding of cAMP
to the PKA regulatory subunits II causes the release of the active
catalytic domain. PKA then phosphorylates GRK2 (circled P), enhanc-
ing its ability to interact with Gbg subunits, thus promoting its trans-
location to the membrane. Once at the membrane, the GRK2-Gbg
complex stabilized by the phosphorylation of GRK2 by PKA can asso-
ciate better with and phosphorylate the agonist-occupied receptor. After
phosphorylation, the b-arrestin proteins bind to the receptor leading to
desensitization and attenuation of G protein coupling.
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form complexes with the b2AR receptor and that it can affect
both receptor desensitization and resensitization (30, 54). It is
not yet clear what the exact role of gravin is in these processes,
but it is likely to be dependent on the ability of gravin to
associate with both second messenger-activated kinases and
specific protein phosphatases. The ability of the b2AR to asso-
ciate with more than one AKAP protein, each with distinct yet
overlapping sets of associated signaling molecules, leads to the
intriguing possibility that different steps during receptor reg-
ulation are modulated by different AKAPs. These steps may
require the physical separation of signaling components onto
distinct scaffolds, allowing entire complexes to be recruited to
the receptor at specific stages during desensitization and re-
sensitization. AKAP79 is constitutively associated with the
b2AR, and thus it may be required at many stages during
receptor regulation (27) including early events such as the
recruitment of GRK2. The association of the receptor with
gravin, however, is regulated by agonist and therefore may be
required for more specific events in the desensitization/resen-
sitization process.
Our studies implicate a role for AKAP79 and PKA in the
regulation of GRK2 recruitment to agonist-occupied b2AR mol-
ecules in a manner that is mediated by the enhanced binding of
GRK2 to Gbg subunits. This function of a scaffold protein and
PKA in the regulation of GRK2 activity represents a novel
mechanism by which two kinases activated during b2AR sig-
naling can influence receptor desensitization.
Acknowledgments—We thank Drs. Randy A. Hall, Richard Premont,
Audrey Claing for helpful discussion, Millie McAdams and Judy Phelps
for DNA sequencing, and Donna Addison and Mary Holben for assist-
ance with the preparation of this manuscript.
REFERENCES
1. Freedman, N. J., and Lefkowitz, R. J. (1996) Recent Prog. Horm. Res. 51,
319–353
2. Benovic, J. L., Pike, L. J., Cerione, R. A., Staniszewski, C., Yoshimasa, T.,
Codina, J., Caron, M. G., and Lefkowitz, R. J. (1985) J. Biol. Chem. 260,
7094–7101
3. Bouvier, M., Leeb-Lundberg, L. M., Benovic, J. L., Caron, M. G., and
Lefkowitz, R. J. (1987) J. Biol. Chem. 262, 3106–3113
4. Hisatomi, O., Matsuda, S., Satoh, T., Kotaka, S., Imanishi, Y., and Tokunaga,
F. (1998) FEBS Lett. 424, 159–164
5. Inglese, J., Freedman, N. J., Koch, W. J., and Lefkowitz, R. J. (1993) J. Biol.
Chem. 268, 23735–23738
6. Pitcher, J., Lohse, M. J., Codina, J., Caron, M. G., and Lefkowitz, R. J. (1992)
Biochemistry 31, 3193–3197
7. Pitcher, J. A., Freedman, N. J., and Lefkowitz, R. J. (1998) Annu. Rev. Bio-
chem. 67, 653–692
8. Weiss, E. R., Raman, D., Shirakawa, S., Ducceschi, M. H., Bertram, P. T.,
Wong, F., Kraft, T. W., and Osawa, S. (1998) Mol. Vis. 4, 27
9. Premont, R. T., Inglese, J., and Lefkowitz, R. J. (1995) FASEB J. 9, 175–182
10. Daaka, Y., Pitcher, J. A., Richardson, M., Stoffel, R. H., Robishaw, J. D., and
Lefkowitz, R. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2180–2185
11. DebBurman, S. K., Ptasienski, J., Benovic, J. L., and Hosey, M. M. (1996)
J. Biol. Chem. 271, 22552–22562
12. DebBurman, S. K., Ptasienski, J., Boetticher, E., Lomasney, J. W., Benovic,
J. L., and Hosey, M. M. (1995) J. Biol. Chem. 270, 5742–5747
13. Koch, W. J., Inglese, J., Stone, W. C., and Lefkowitz, R. J. (1993) J. Biol. Chem.
268, 8256–8260
14. Pitcher, J. A., Inglese, J., Higgins, J. B., Arriza, J. L., Casey, P. J., Kim, C.,
Benovic, J. L., Kwatra, M. M., Caron, M. G., and Lefkowitz, R. J. (1992)
Science 257, 1264–1267
15. Pitcher, J. A., Fredericks, Z. L., Stone, W. C., Premont, R. T., Stoffel, R. H.,
Koch, W. J., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 24907–24913
16. Pitcher, J. A., Touhara, K., Payne, E. S., and Lefkowitz, R. J. (1995) J. Biol.
Chem. 270, 11707–11710
17. Pawson, T., and Scott, J. D. (1997) Science 278, 2075–2080
18. Colledge, M., and Scott, J. (1999) Trends Cell Biol. 9, 216–221
19. Li, Y., Ndubuka, C., and Rubin, C. S. (1996) J. Biol. Chem. 271, 16862–16869
20. Carr, D. W., Stofko-Hahn, R. E., Fraser, I. D., Cone, R. D., and Scott, J. D.
(1992) J. Biol. Chem. 267, 16816–16823
21. Fraser, I., Tavalin, S., Lester, L., Langeberg, L., Westphal, A., Dean, R.,
Marrio, N., and Scott, J. (1998) EMBO J. 17, 2261–2272
22. Chen, Q., Lin, R. Y., and Rubin, C. S. (1997) J. Biol. Chem. 272, 15247–15257
23. Huang, L. J.-S., Durick, K., Weiner, J. A., Chun, J., and Taylor, S. S. (1997
J. Biol. Chem. 272, 8057–8064
24. Lin, R.-Y., Moss, S. B., and Rubin, C. S. (1995) J. Biol. Chem. 270,
27804–27811
25. Takahashi, M., Shibata, H., Shimakawa, M., Miyamoto, M., Mukai, H., and
Ono, Y. (1999) J. Biol. Chem. 274, 17267–17274
26. Huang, L. J., Wang, L., Ma, Y., Durick, K., Perkins, G., Deerinck, T. J.,
Ellisman, M. H., and Taylor, S. S. (1999) J. Cell Biol. 145, 951–959
27. Fraser, I. D., Cong, M., Kim, J., Rollins, E. N., Daaka, Y., Lefkowitz, R. J., and
Scott, J. D. (2000) Curr. Biol. 10, 409–412
28. Westphal, R. S., Tavalin, S. J., Lin, J. W., Alto, N. M., Fraser, I. D., Langeberg,
L. K., Sheng, M., and Scott, J. D. (1999) Science 285, 93–96
29. Ratcliffe, C. F., Qu, Y., McCormick, K. A., Tibbs, V. C., Dixon, J. E., Scheuer,
T., and Catterall, W. A. (2000) Nat. Neurosci. 3, 437–444
30. Shih, M., Lin, F., Scott, J., Wang, H., and Malbon, C. (1999) J. Biol. Chem. 274,
1588–1595
31. Gray, P., Scott, J., and Catterall, W. (1998) Curr. Opin. Neurobiol. 8, 330–334
32. Gray, P. C., Tibbs, V. C., Catterall, W. A., and Murphy, B. J. (1997) J. Biol.
Chem. 272, 6297–6302
33. Gray, P., Johnson, B., Westenbroek, R., Hays, L., Yates, J. R., Scheuer, T.,
Catterall, W., and Murphy, B. (1998) Neuron 20, 1017–1026
34. Faux, M. C., and Scott, J. D. (1996) Cell 85, 9–12
35. Faux, M. C., and Scott, J. D. (1997) J. Biol. Chem. 272, 17038–17044
36. Coghlan, V., Perrino, B., Howard, M., Langeberg, L., Hicks, J., Gallatin, W.,
and Scott, J. (1995) Science 267, 108–112
37. Klauck, T. M., Faux, M. C., Labudda, K., Langeberg, L. K., Jaken, S., and
Scott, J. D. (1996) Science 271, 1589–1592
38. Kim, C. M., Dion, S. B., Onorato, J. J., and Benovic, J. L. (1993) Receptor 3,
39–55
39. Papermaster, D., and Dreyer, W. (1974) Biochemistry 13, 2438–2444
40. Casey, P., Graziano, M., and Gilman, A. (1989) Biochemistry 28, 611–616
41. Simon, J., Parsons, S., and Salmon, E. (1991) Micron Microsc. Acta 22,
405–412
42. Oppermann, M., Diverse-Pierluissi, M., Drazner, M. H., Dyer, S. L., Freedman,
N. J., Peppel, K. C., and Lefkowitz, R. J. (1996) Proc. Natl. Acad. Sci.
U. S. A. 93, 7649–7654
43. Freedman, N. J., Liggett, S. B., Drachman, D. E., Pei, G., Caron, M. G., and
Lefkowitz, R. J. (1995) J. Biol. Chem. 270, 17953–17961
44. Pitcher, J. A., Tesmer, J. J., Freeman, J. L., Capel, W. D., Stone, W. C., and
Lefkowitz, R. J. (1999) J. Biol. Chem. 274, 34531–34534
45. Freedman, N. J., Ament, A. S., Oppermann, M., Stoffel, R. H., Exum, S. T., and
Lefkowitz, R. J. (1997) J. Biol. Chem. 272, 17734–17743
46. Barak, L. S., Tiberi, M., Freedman, N. J., Kwatra, M. M., Lefkowitz, R. J., and
Caron, M. G. (1994) J. Biol. Chem. 269, 2790–2795
47. Pitcher, J. A., Hall, R. A., Daaka, Y., Zhang, J., Ferguson, S. S., Hester, S.,
Miller, S., Caron, M. G., Lefkowitz, R. J., and Barak, L. S. (1998) J. Biol.
Chem. 273, 12316–12324
48. Ferguson, S. S., Menard, L., Barak, L. S., Koch, W. J., Colapietro, A. M., and
Caron, M. G. (1995) J. Biol. Chem. 270, 24782–24789
49. Chuang, T. T., LeVine, H., III, and De Blasi, A. (1995) J. Biol. Chem. 270,
18660–18665
50. Winstel, R., Freund, S., Krasel, C., Hoppe, E., and Lohse, M. J. (1996) Proc.
Natl. Acad. Sci. U. S. A. 93, 2105–2109
51. Haske, T. N., DeBlasi, A., and LeVine, H. (1996) J. Biol. Chem. 271, 2941–2948
52. Muller, S., Hekman, M., and Lohse, M. J. (1993) Proc. Natl. Acad. Sci. U. S. A.
90, 10439–10443
53. Pronin, A. N., and Benovic, J. L. (1997) J. Biol. Chem. 272, 3806–3812
54. Lin, F., Wang, H., and Malbon, C. (2000) J. Biol. Chem. 275, 19025–19034
PKA Regulation of GRK2 15199
